Histone Deacetylase (HDAC) Inhibitory and Antiproliferative Activities of Phenolic-rich Extracts Derived from the Rhizome of Hydnophytum Formicarum Jack.: Sinapinic Acid Acts As HDAC Inhibitor

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2013 Sep 24

PMID 24053181

Citations 18

Authors

Thanaset Senawong

Suwatchai Misuna

Somprasong Khaopha

Suporn Nuchadomrong

Prasan Sawatsitang

Chanokbhorn Phaosiri

Arpa Surapaitoon

Banchob Sripa

Affiliations

Soon will be listed here.

Abstract

Background: The rhizome of Hydnophytum formicarum Jack., a medicinal plant known in Thai as Hua-Roi-Roo, has been used in Thai traditional herbal medicine for treatment of cancer. We assessed the ability of its ethanolic and phenolic-rich extracts and its major phenolic compound, sinapinic acid, possessing histone deacetylase (HDAC) inhibitory activity to inhibit proliferation of 5 human cancer cell lines.

Methods: HeLa cells were used to study HDAC inhibitory activity of the extracts, sinapinic acid, and a well-known HDAC inhibitor sodium butyrate. Five human cancer cell lines and one non-cancer cell line were used to study antiproliferative activities of the plant extracts, sinapinic acid and sodium butyrate, comparatively.

Results: Results indicated that ethanolic and phenolic-rich extracts of H. formicarum Jack. rhizome possessed both antiproliferative activity and HDAC inhibitory activity in HeLa cells. Sinapinic acid, despite its lower HDAC inhibitory activity than the well-known HDAC inhibitor sodium butyrate, inhibited the growth of HeLa and HT29 cells more effectively than sodium butyrate. However, sinapinic acid inhibited the growth of HCT116 and Jurkat cells less effectively than sodium butyrate. The non-cancer cell line (Vero cells) and breast cancer cell line (MCF-7 cells) appeared to be resistant to both sinapinic acid and sodium butyrate. The growth inhibitory effects of the ethanolic and phenolic-rich extracts and sinapinic acid in HeLa cells were mediated by induction of apoptosis.

Conclusions: The results of this study support the efficacy of H. formicarum Jack. rhizome ethanolic and phenolic-rich extracts for the treatment of cervical cancer, colon cancer, and T- cell leukemia in an alternative medicine. Further studies of other active ingredients from this plant are needed.

Citing Articles

Sinapic-Acid-Loaded Nanoparticles Optimized via Experimental Design Methods: Cytotoxic, Antiapoptotoic, Antiproliferative, and Antioxidant Activity.

Poyraz F, Akbas G, Duranoglu D, Acar S, Mansuroglu B, Ersoz M ACS Omega. 2024; 9(39):40329-40345.

PMID: 39371991 PMC: 11447863. DOI: 10.1021/acsomega.4c00216.

Anticancer Potential of Valencia Peanut ( L.) Skin Extract against Cervical Cancer Cells In Vitro and in Nude Mouse Xenograft Models.

Jeeunngoi J, Senawong G, Jogloy S, Prompipak J, Samankul A, Utaiwat S Foods. 2024; 13(15).

PMID: 39123546 PMC: 11312182. DOI: 10.3390/foods13152354.

Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis.

Khanal M, Acharya A, Maharjan R, Gyawali K, Adhikari R, Das Mulmi D PLoS One. 2024; 19(7):e0307501.

PMID: 39037973 PMC: 11262678. DOI: 10.1371/journal.pone.0307501.

Biotransformation technology and high-value application of rapeseed meal: a review.

Yang Z, Huang Z, Cao L Bioresour Bioprocess. 2024; 9(1):103.

PMID: 38647572 PMC: 10991624. DOI: 10.1186/s40643-022-00586-4.

Toxicity prediction and analysis of flavonoid apigenin as a histone deacetylase inhibitor: an in-silico approach.

Divya Rajaselvi N, Jida M, Nair D, Sujith S, Beegum N, Nisha A In Silico Pharmacol. 2023; 11(1):34.

PMID: 37941890 PMC: 10630278. DOI: 10.1007/s40203-023-00170-4.

References

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

Smith J, Brachmann C, Celic I, Kenna M, Muhammad S, Starai V . A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A. 2000; 97(12):6658-63. PMC: 18692. DOI: 10.1073/pnas.97.12.6658. View

Lin H, Chen C, Lin S, Weng J, Chen C . Targeting histone deacetylase in cancer therapy. Med Res Rev. 2006; 26(4):397-413. DOI: 10.1002/med.20056. View

Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, Aranda A . Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol. 2008; 10(7):395-8. DOI: 10.1007/s12094-008-0221-x. View

Jiao J, Fang H, Wang X, Guan P, Yuan Y, Xu W . Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur J Med Chem. 2009; 44(11):4470-6. DOI: 10.1016/j.ejmech.2009.06.010. View

Riester D, Hildmann C, Schwienhorst A . Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol. 2007; 75(3):499-514. DOI: 10.1007/s00253-007-0912-1. View

Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D . Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2007; 19(9):587-93. DOI: 10.1016/j.jnutbio.2007.08.002. View

Manosroi J, Boonpisuttinant K, Manosroi W, Manosroi A . Anti-proliferative activities on HeLa cancer cell line of Thai medicinal plant recipes selected from MANOSROI II database. J Ethnopharmacol. 2012; 142(2):422-31. DOI: 10.1016/j.jep.2012.05.012. View

Cheriyath V, Kuhns M, Kalaycio M, Borden E . Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer. 2011; 104(6):957-67. PMC: 3065279. DOI: 10.1038/bjc.2011.42. View

10.

Itharat A, Houghton P, Eno-Amooquaye E, Burke P, Sampson J, Raman A . In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol. 2003; 90(1):33-8. DOI: 10.1016/j.jep.2003.09.014. View

11.

Kretzner L, Scuto A, Dino P, Kowolik C, Wu J, Ventura P . Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011; 71(11):3912-20. PMC: 3107377. DOI: 10.1158/0008-5472.CAN-10-2259. View

12.

Carew J, Giles F, Nawrocki S . Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008; 269(1):7-17. DOI: 10.1016/j.canlet.2008.03.037. View

13.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

14.

de Ruijter A, van Gennip A, Caron H, Kemp S, van Kuilenburg A . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2002; 370(Pt 3):737-49. PMC: 1223209. DOI: 10.1042/BJ20021321. View

15.

Rasheed W, Johnstone R, Prince H . Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007; 16(5):659-78. DOI: 10.1517/13543784.16.5.659. View

16.

Gawlik-Dziki U, Swieca M, Dziki D . Comparison of phenolic acids profile and antioxidant potential of six varieties of spelt (Triticum spelta L.). J Agric Food Chem. 2012; 60(18):4603-12. DOI: 10.1021/jf3011239. View

17.

Prachayasittikul S, Buraparuangsang P, Worachartcheewan A, Isarankura-Na-Ayudhya C, Ruchirawat S, Prachayasittikul V . Antimicrobial and antioxidative activities of bioactive constituents from Hydnophytum formicarum Jack. Molecules. 2008; 13(4):904-21. PMC: 6245381. DOI: 10.3390/molecules13040904. View

18.

Bora-Tatar G, Dayangac-Erden D, Demir A, Dalkara S, Yelekci K, Erdem-Yurter H . Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorg Med Chem. 2009; 17(14):5219-28. DOI: 10.1016/j.bmc.2009.05.042. View

19.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N . Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2007; 409(2):581-9. DOI: 10.1042/BJ20070779. View

20.

Dayangac-Erden D, Bora G, Ayhan P, Kocaefe C, Dalkara S, Yelekci K . Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des. 2009; 73(3):355-64. DOI: 10.1111/j.1747-0285.2009.00781.x. View